Veracyte, Inc. (NASDAQ:VCYT) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET
Company Participants
Shayla Gorman – Senior Director, Investor Relations
Marc Stapley – Chief Executive Officer
Rebecca Chambers – Chief Financial Officer
Conference Call Participants
Mason Carrico – Stephens, Inc.
Yuko Oku – Morgan Stanley
Maggie Boeye – William Blair
Joseph Conway – Needham & Company
Prashant Kota – Goldman Sachs
Thomas DeBourcy – Nephron Research
Operator
Good day and thank you for standing by. Welcome to the Veracyte Second Quarter 2024 Financial Results Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your first speaker today, Shayla Gorman, Senior Director, Investor Relations. Please go ahead.
Shayla Gorman
Good afternoon everyone, and thank you for joining us today for a discussion of our second quarter 2024 financial results. With me today are Marc Stapley, Veracyte’s Chief Executive Officer; and Rebecca Chambers, our Chief Financial Officer. Veracyte issued a press release earlier this afternoon detailing our second quarter 2024 financial results. This release along with the business and financial presentation is available in the Investor Relations section of our website at veracyte.com.
Before we begin, I’d like to remind you that various statements that we may make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements are subject to risks and uncertainties and the company can give no assurance they will prove to be correct. Additionally, we are not under any obligation to provide further updates on our business trends or our performance during the quarter. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Veracyte files with the Securities and Exchange Commission, including Veracyte’s most recent Forms 10-Q and 10-K.
In addition, this call will include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures are included in today’s earnings release accessible from the IR section of Veracyte’s website. This quarter we have updated our non-GAAP measures to exclude stock-based compensation to provide better comparison to our peers and help investors gain a better understanding of our performance. Further, all comparisons to prior periods are to the updated non-GAAP metrics that excludes stock-based compensation. We have included a schedule of the non-GAAP adjustments for prior periods in today’s earnings presentation available on the Investors section of our website.